scholarly journals Genomic Alterations in Human Papillomavirus–Positive and –Negative Conjunctival Squamous Cell Carcinomas

2021 ◽  
Vol 62 (14) ◽  
pp. 11
Author(s):  
Ingvild Ramberg ◽  
Filipe Garrett Vieira ◽  
Peter Bjerre Toft ◽  
Christian von Buchwald ◽  
Mikkel Funding ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Genomic Alterations

scholarly journals Human papillomavirus in head and neck squamous cell carcinomas in a South African cohort

2018 ◽  
Vol 6 ◽  
pp. 58-62 ◽  
Author(s):  
Tumelo R. Sekee ◽  
Felicity J. Burt ◽  
Dominique Goedhals ◽  
Jacqueline Goedhals ◽  
Yuri Munsamy ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
South African ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas

Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina

2012 ◽  
Vol 125 (1) ◽  
pp. 194-199 ◽  
Author(s):  
Immaculada Alonso ◽  
Ana Felix ◽  
Aureli Torné ◽  
Victoria Fusté ◽  
Marta del Pino ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Squamous Cell ◽  
Prognostic Biomarker ◽  
Squamous Cell Carcinomas

Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline

2018 ◽  
Vol 36 (31) ◽  
pp. 3152-3161 ◽  
Author(s):  
Carole Fakhry ◽  
Christina Lacchetti ◽  
Lisa M. Rooper ◽  
Richard C. Jordan ◽  
Danny Rischin ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Expert Panel ◽  
Surrogate Marker ◽  
Squamous Cell Carcinomas ◽  
Head Neck Cancer ◽  
Hpv Testing ◽  
Head And Neck Carcinomas

Purpose The College of American Pathologists produced an evidence-based guideline on testing, application, interpretation, and reporting of human papillomavirus (HPV) and surrogate marker tests in head and neck carcinomas that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. Methods The College of American Pathologists HPV Testing in Head and Neck Carcinomas guideline was reviewed by ASCO content experts for clinical accuracy and by methodologists for developmental rigor. On favorable review, an ASCO Expert Panel was convened to review the guideline contents and recommendations. Results The ASCO Expert Panel determined that the recommendations from the HPV Testing in Head and Neck Carcinomas guideline, published in 2018, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the guideline and added minor qualifying statements. Recommendations It is recommended that HPV tumor status should be determined for newly diagnosed oropharyngeal squamous cell carcinomas. HPV tumor status testing may be performed by surrogate marker p16 immunohistochemistry either on the primary tumor or from cervical nodal metastases only if an oropharyngeal primary tumor is present. The threshold for positivity is at least 70% nuclear and cytoplasmic expression with at least moderate to strong intensity. Additional confirmatory testing may be done at the discretion of the pathologist and/or treating clinician. Pathologists should not routinely determine HPV tumor status in nonsquamous carcinomas of the oropharynx or non–oropharyngeal squamous cell carcinomas of the head and neck. When there is uncertainty of histologic type or whether a poorly differentiated oropharyngeal tumor is nonsquamous, HPV tumor status testing may be warranted and at the discretion of the pathologist and/or treating clinician. Additional information is available at: www.asco.org/head-neck-cancer-guidelines .

Sign in / Sign up

Export Citation Format

Share Document